Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug
Back to News
AlphaMaven Alternative Investment News
Hedge Fund Private Equity

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

dealbreaker
4 months ago
57 views
Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could offer a dosing edge over blockbuster asthma medicines currently available, and the company now has $400 million in IPO cash to support two ongoing pivotal clinical trials.Late Thursday, Somerville, Mass.-based Generate priced its offering of 25 million shares at $16 each, which was the midpoint of the p...

Continue Reading

Sign up for FREE to read the full article and access 134K+ alternative investment headlines.

Create Free Account Login

Not a member yet?

Why AlphaMaven

The Premier Alternative
Investment Platform

Research & Due Diligence for Qualified Investors

Free Membership for Qualified Investors & Industry Participants
Personalized Content
Breaking News 24/7
Daily Newsletter & Indices
Investment Listings
Company & Contact Directory
Member Publications
Alpha University Videos
AUM Accelerator Program
Due Diligence, Webinars, Events & LeaderBoards
147K+
News & Posts
24K+
Investor Profiles
24/7
Coverage
Sign Up Now

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.